Proteasome inhibitors are the backbone in the treatment of multiple myeloma with 3 of its representatives (bortezomib, carfilzomib, and ixazomib) having already been approved. There is a different situation altogether in the treatment of amyloid light chain (AL) amyloidosis where owing to the rarity of this entity neither of these drugs has currently gained approval. Amyloid light chain plasma cells are possibly more vulnerable to bortezomib than myeloma plasmocytes because of a slightly distinct mechanism of action, which is described in depth in this manuscript. Bortezomib is highly active and rapidly effective as a single agent and even more potent in combination with dexamethasone and alkylators. Bortezomib-based regimens have become a standard part of the initial treatment of AL amyloidosis in the majority of centers. We have reviewed all available data on bortezomib in various combinations and settings. Carfilzomib seems to be effective but also toxic in these fragile patients with a high rate of cardiac events. Oral ixazomib has shown a surprisingly high efficacy with manageable toxicity and has received the Food and Drug Administration Breakthrough Therapy designation in 2014 for relapsed AL amyloidosis patients. In this review we have comprehensively described the current available knowledge of these 3 proteasome inhibitors and their use in AL amyloidosis.

Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic Faculty of Medicine University of Ostrava Ostrava Czech Republic

Faculty of Medicine University of Ostrava Ostrava Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc18011018

003      

CZ-PrNML

005      

20180417093505.0

007      

ta

008      

180404s2017 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1002/hon.2351 $2 doi

035    __

$a (PubMed)27647123

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Jelinek, T $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic. Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

245    10

$a Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity / $c T. Jelinek, E. Kryukova, Z. Kufova, F. Kryukov, R. Hajek,

520    9_

$a Proteasome inhibitors are the backbone in the treatment of multiple myeloma with 3 of its representatives (bortezomib, carfilzomib, and ixazomib) having already been approved. There is a different situation altogether in the treatment of amyloid light chain (AL) amyloidosis where owing to the rarity of this entity neither of these drugs has currently gained approval. Amyloid light chain plasma cells are possibly more vulnerable to bortezomib than myeloma plasmocytes because of a slightly distinct mechanism of action, which is described in depth in this manuscript. Bortezomib is highly active and rapidly effective as a single agent and even more potent in combination with dexamethasone and alkylators. Bortezomib-based regimens have become a standard part of the initial treatment of AL amyloidosis in the majority of centers. We have reviewed all available data on bortezomib in various combinations and settings. Carfilzomib seems to be effective but also toxic in these fragile patients with a high rate of cardiac events. Oral ixazomib has shown a surprisingly high efficacy with manageable toxicity and has received the Food and Drug Administration Breakthrough Therapy designation in 2014 for relapsed AL amyloidosis patients. In this review we have comprehensively described the current available knowledge of these 3 proteasome inhibitors and their use in AL amyloidosis.

650    _2

$a lidé $7 D006801

650    _2

$a primární amyloidóza $x farmakoterapie $x patologie $7 D000075363

650    _2

$a mnohočetný myelom $x farmakoterapie $x patologie $7 D009101

650    _2

$a inhibitory proteasomu $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D061988

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

700    1_

$a Kryukova, E $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

700    1_

$a Kufova, Z $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic. Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

700    1_

$a Kryukov, F $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

700    1_

$a Hajek, R $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic. Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

773    0_

$w MED00002019 $t Hematological oncology $x 1099-1069 $g Roč. 35, č. 4 (2017), s. 408-419

856    41

$u https://pubmed.ncbi.nlm.nih.gov/27647123 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20180404 $b ABA008

991    __

$a 20180417093604 $b ABA008

999    __

$a ok $b bmc $g 1288503 $s 1007830

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2017 $b 35 $c 4 $d 408-419 $e 20160920 $i 1099-1069 $m Hematological oncology $n Hematol Oncol $x MED00002019

GRA    __

$a NV15-29667A $p MZ0

LZP    __

$a Pubmed-20180404